We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Research Initiative to Improve Cancer Diagnosis, Therapy

By HospiMedica staff writers
Posted on 02 Mar 2005
The University of Pennsylvania (Penn; Philadelphia, PA, USA) has recently been chosen to become a member of the U.S. More...
National Cancer Institute's (NCI) Mouse Models of Human Cancers Consortium (MMHCC; Frederick, MD, USA).

As a member of the Consortium, the Penn team of scientists' strategy is to develop conceptual and technical approaches for determining the processes of breast tumor progression and metastasis. To achieve this goal, they will utilize a wide range of state-of-the-art molecular and cellular imaging methods to assess a series of novel, genetically engineered mouse models of breast cancer. "This type of endeavor requires a group of scientists with a tremendous breadth of knowledge and expertise, which this grant has allowed us to assemble,” stated Lewis A. Chodosh, M.D., Ph.D., vice chair, department of cancer biology, at the Abramson Cancer Center at Penn. Dr. Chodosh.

The Penn MMHCC team will specifically use a wide-ranging array of advanced technologies including magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance spectroscopy (MRS), and ultrasound to visualize and track tumor cells in living animals from their origins to their gradual progression to distant metastasis and recurrence.

The technology will also be utilized to evaluate tumor response to therapy and to predict clinical outcomes. The mouse models to be used in this project are distinctive in that the investigators can follow the complete natural history in each animal--from the initial onset to response to therapy, tumor dormancy, and ultimately, metastasis and recurrence.

Advanced stages of tumor progression, typified by resistance to therapeutic drugs, metastasis, and tumor recurrence, are responsible for most of cancer deaths. Whereas tumor progression, however, comprises a problem of incredible clinical significance, the underlying processes are basically unknown. Understanding more about the physiologic and molecular events that add to this mechanism is a crucial priority in cancer research.





Related Links:
The University of Pennsylvania
MMHCC

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Surgical Headlight
IsoTorch
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.